Pembrolizumab in a BRAF-mutant metastatic melanoma patient following a severe immune-related adverse event with ipilimumab.
Currently, limited data exist on the safety of pembrolizumab in patients with metastatic melanoma who have developed severe immune-related adverse events following treatment with ipilimumab. We report a 45-year-old male patient with BRAF-mutant metastatic melanoma who discontinued treatment with ipilimumab due to treatment-related grade 3 colitis and was subsequently treated with the anti-programmed cell death 1 protein (PD-1) antibody pembrolizumab. He has been on treatment with pembrolizumab for more than 20 months with no major toxicities and has achieved an objective partial response, which is ongoing.
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Francisco
F
Aya
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Aranzazu
A
Fernández-Martínez
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Lydia
L
Gaba
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Iván
I
Victoria
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Mónica
M
Tosca
Dermatology Department, Hospital Clinic Barcelona, Barcelona, Spain.|CIBER Enfermedades Raras, Instituto de Salud Carlos III, Spain, Madrid, Spain.|University of Barcelona, Barcelona, Spain.
Cristina
C
Carrera
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Aleix
A
Prat
Medical Oncology Department, Hospital Clinic Barcelona, Barcelona, Spain.|Translational Genomics & Targeted Therapeutics in Solid Tumors, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Ana
A
Arance
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D060908:CTLA-4 Antigen / Q000276:immunology; D003092:Colitis / Q000188:drug therapy* / Q000209:etiology; D064420:Drug-Related Side Effects and Adverse Reactions / Q000188:drug therapy*; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000150:complications / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation / Q000235:genetics; D009362:Neoplasm Metastasis; D061026:Programmed Cell Death 1 Receptor / Q000276:immunology; D048493:Proto-Oncogene Proteins B-raf / Q000235:genetics; D011788:Quality of Life; D028761:Withholding Treatment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D060908:CTLA-4 Antigen; D000074324:Ipilimumab; C491383:Pdcd1 protein, mouse; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab; C482119:BRAF protein, human; D048493:Proto-Oncogene Proteins B-raf
anti-CTLA-4; anti-PD-1; immune-related adverse event; melanoma